Kenji Yasukawa
Profile
Performance in office
Tenure
Tenure
Background
He joined the company in April 1986, became an Executive Officer in June 2010 and Senior Executive Officer in June 2012. He became Representative Director and Executive Vice President in June 2017 and Representative Director and President in April 2018. It was 32 years from joining to the presidency and eight years from becoming an Executive Officer. Astellas Pharma was formed through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical in April 2005, and Kenji Yasukawa was President 13 years after the merger.
Selection
In April 2018 he became Representative Director and President, succeeding Yoshihiko Hatanaka. In the fiscal year ended March 2018, the year before he took office, consolidated revenue was ¥1,300.3 billion, operating income ¥213.3 billion and net income ¥164.6 billion. Revenue had fallen for two straight years from ¥1,372.7 billion in FY ended March 2016, and employees had fallen by 600, from 17,217 to 16,617. The promotion came ten months after he became Representative Director and Executive Vice President.
Initiatives
His tenure lasted five years, from April 2018 to April 2023. Consolidated revenue grew by ¥218.3 billion, from ¥1,300.3 billion in the year before he took office to ¥1,518.6 billion in the fiscal year ended March 2023. Operating income, however, fell from ¥213.3 billion to ¥133.0 billion and net income from ¥164.6 billion to ¥98.7 billion. Employees fell by 2,133, from 16,617 to 14,484. Revenue of ¥1,249.5 billion in FY ended March 2021 was the lowest of his tenure.
Career
Career
Astellas Pharma
| Date | Position |
|---|---|
| Apr 1986 | Joined |
| Jun 2010 | Executive Officer |
| Jun 2012 | Senior Executive Officer |
| Jun 2017 | Representative Director, Executive Vice President |
| Apr 2018 | Representative Director, President |
| Apr 2023 | Representative Director, Chairman |
| Apr 2023 | Stepped down as President |
References 1
References (Japanese primary sources)
- アステラス製薬 有価証券報告書（役員の状況）